This clinical trial is focused on studying a new treatment for patients with unresectable locally advanced or metastatic cancer. The treatment being tested is called TAK-280, which is a solution given through an intravenous infusion, meaning it is administered directly into the bloodstream. The study aims to understand how safe and tolerable TAK-280 is for patients, and to find the most suitable dose for future use.

During the trial, participants will receive TAK-280 and will be closely monitored by healthcare professionals. The study will also involve other medications like Tocilizumab and Siltuximab, which are also given through intravenous infusion. Some participants may receive a placebo instead of the active medication. The trial will help researchers learn more about how TAK-280 affects the body and how it might help in treating cancer.

Participants will visit the study site regularly for treatment and check-ups. These visits will allow the research team to monitor the participants’ health and any side effects they might experience. The study is expected to last for several months, and the information gathered will contribute to understanding the potential benefits and risks of TAK-280 for treating advanced cancer.